{"input_url":"https://pharmatimes.com/news/teitur-reports-positive-early-data-for-parkinsons-peptide-tt-p34/","gnews_decode":"https://pharmatimes.com/news/teitur-reports-positive-early-data-for-parkinsons-peptide-tt-p34/","http_status":200,"final_url":"https://pharmatimes.com/news/teitur-reports-positive-early-data-for-parkinsons-peptide-tt-p34/","html_length":452477,"trafilatura_result":"ok","text_length":2241,"text_preview":"Teitur Trophics has announced successful results from its phase 1 clinical trial of TT‑P34, a first‑in‑class peptide being developed for Parkinson’s disease. The study, conducted in healthy volunteers and patients with early‑stage Parkinson’s, showed the therapy was safe and well tolerated, with pha","verdict":"OK"}